[
  {
    "ts": null,
    "headline": "Defensive stocks show deep value as cyclicals run hot, UBS says",
    "summary": "Investing.com-- Defensive plays like healthcare equipment and benchmark pharma now offer deeper value at a time when cyclical sectors are trading at historically expensive levels and are pricing in a sharp earnings reboundd despite cooling domestic demand in the US and stuttering Eurozone growth.",
    "url": "https://finnhub.io/api/news?id=300a7d1ba24a858c5d5180f6f3699881c6a595516e286d122c70b6d81d3452bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759266097,
      "headline": "Defensive stocks show deep value as cyclicals run hot, UBS says",
      "id": 136944126,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Investing.com-- Defensive plays like healthcare equipment and benchmark pharma now offer deeper value at a time when cyclical sectors are trading at historically expensive levels and are pricing in a sharp earnings reboundd despite cooling domestic demand in the US and stuttering Eurozone growth.",
      "url": "https://finnhub.io/api/news?id=300a7d1ba24a858c5d5180f6f3699881c6a595516e286d122c70b6d81d3452bb"
    }
  },
  {
    "ts": null,
    "headline": "Piper Sandler Reaffirms its Overweight Rating and $115 Price Target on Boston Scientific Corporation (BSX)",
    "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the 14 Stocks That Will Double in the Next 5 Years. On September 25, 2025, Piper Sandler reaffirmed its Overweight rating and $115 price target on Boston Scientific Corporation (NYSE:BSX), a $145.3 billion medical products company, citing confidence in the CHAMPION-AF study as a major growth driver for its Watchman […]",
    "url": "https://finnhub.io/api/news?id=f662e76fc40558040139a7e5abb92731a14e028610c24ebcb4c50a8718fcbc24",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759265871,
      "headline": "Piper Sandler Reaffirms its Overweight Rating and $115 Price Target on Boston Scientific Corporation (BSX)",
      "id": 136944233,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the 14 Stocks That Will Double in the Next 5 Years. On September 25, 2025, Piper Sandler reaffirmed its Overweight rating and $115 price target on Boston Scientific Corporation (NYSE:BSX), a $145.3 billion medical products company, citing confidence in the CHAMPION-AF study as a major growth driver for its Watchman […]",
      "url": "https://finnhub.io/api/news?id=f662e76fc40558040139a7e5abb92731a14e028610c24ebcb4c50a8718fcbc24"
    }
  },
  {
    "ts": null,
    "headline": "2025 Investor Day Call",
    "summary": "2025-09-30. The following slide deck was published by Boston Scientific Corporation in conjunction with this event.",
    "url": "https://finnhub.io/api/news?id=114bd8abbc7d7ecb7be23669b4974bae08654d4b74cc086862866b7a1daa1164",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759256594,
      "headline": "2025 Investor Day Call",
      "id": 136940143,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "2025-09-30. The following slide deck was published by Boston Scientific Corporation in conjunction with this event.",
      "url": "https://finnhub.io/api/news?id=114bd8abbc7d7ecb7be23669b4974bae08654d4b74cc086862866b7a1daa1164"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific Corporation (BSX) Analyst/Investor Day Transcript",
    "summary": "Discover Boston Scientific's latest investor insights, 3-year growth strategies",
    "url": "https://finnhub.io/api/news?id=324331614c1d8a5a22398b3258bc5dc59b13014cfaa81627e93f295b4029b9cd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759255927,
      "headline": "Boston Scientific Corporation (BSX) Analyst/Investor Day Transcript",
      "id": 136940070,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Discover Boston Scientific's latest investor insights, 3-year growth strategies",
      "url": "https://finnhub.io/api/news?id=324331614c1d8a5a22398b3258bc5dc59b13014cfaa81627e93f295b4029b9cd"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Reiterates Boston Scientific (BSX) Outperform Recommendation",
    "summary": "RBC Capital Reiterates Boston Scientific (BSX) Outperform Recommendation",
    "url": "https://finnhub.io/api/news?id=84c51ffc2f6079ad8bf8b91a404d1a4996c51a1d8c4ececf0bf0af64d7ca39c5",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759190798,
      "headline": "RBC Capital Reiterates Boston Scientific (BSX) Outperform Recommendation",
      "id": 136919597,
      "image": "",
      "related": "BSX",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=84c51ffc2f6079ad8bf8b91a404d1a4996c51a1d8c4ececf0bf0af64d7ca39c5"
    }
  }
]